Analyst consensus rating
Viridian Therapeutics Analyst Rating: Strong Buy
Direct answer
Viridian Therapeutics's consensus rating is Strong Buy.
16 analysts are included in the current consensus when a coverage count is available.
The same consensus reports an average price target of $36.75.
Forecast evidence checked September 23, 2026.
Get free Viridian Therapeutics email updates.
Bullstory sends one daily email when new analysis or important company news is available.
Verified data
- Current price
- $21.47
- Average price target
- $36.75
- High price target
- $50.00
- Low price target
- $22.00
- Low target gap
- +2.5%
- Target upside
- +71.2%
- High target gap
- +132.9%
- Target range width
- 130.4%
- Consensus rating
- Strong Buy
- Analysts
- 16
- Evidence date
- September 23, 2026
- Valid through
- September 30, 2026
Explore related company data
Read the frequently asked questions.
What is the analyst consensus rating for Viridian Therapeutics?
Viridian Therapeutics has a verified Strong Buy consensus. The same dataset has an average price target of $36.75.
How far are Viridian Therapeutics's low and high targets from the recorded price?
The low target implies +2.5%, while the high target implies +132.9%.
How many analysts are included in Viridian Therapeutics's consensus?
The verified consensus includes 16 analysts.
How is Viridian Therapeutics's target upside or downside calculated?
The average target of $36.75 is divided by the recorded price of $21.47, then one is subtracted to produce +71.2%. This does not guarantee a future return.
When was Viridian Therapeutics's analyst forecast verified?
The data was verified on 2026-09-23. The dataset is valid through 2026-09-30.